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 Summary 
 
Histological regression and tumour infiltrating lymphocytes represent an early sign of activation of the 
immune system against primary melanoma. The first phenomenon has been especially discussed in the 
literature because of its prognostic role, but no clear agreement on its evaluation has been reached. 
Immunotherapy of advanced stage melanoma has recently shown promising results; an improved 
understanding of the initial interplay between melanoma cells and the immune system would 
potentially help tailor treatment for patients.  
Seventy consecutive melanomas with regression were analysed to identify a prognostic cut-off value of 
regression extension.  Then, we compared the immune infiltrate between regressed and not regressed 
areas of these regressed melanomas, assessing CD3, CD4, CD8, CD20, CD123, PD1 and 
FOXP3/CD25 expression.  The immune infiltrate of these cases was further compared with 28 control 
melanomas without regression.   
A regression extension of 10% represented a reliable cut-off to distinguish two different risk categories 
in regressed melanomas. Regressed areas were less infiltrated by CD4/CD25, FOXP3/CD4 or   
PD1/CD4 compared to not regressed areas of each sample. These lymphocyte subsets are associated 
with anergy and hamper the immune CD8+ response towards the cancer cells. Moreover, the relevance 
of these findings was further supported by the observation that not regressed controls were significantly 
more infiltrated by these anergic immune cell subsets compared to the regressed cases.   
These results help understand the real meaning of regression in melanoma. Moreover, the association 
here identified between specific immunomodulatory immune cell subsets and regression could help 
devise new therapeutic strategies. 
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INTRODUCTION 
 
Despite extensive efforts aimed at identifying prognostic biomarkers in melanoma, its clinical 
behaviour remains often unpredictable with frequent unexpected progressions, both in terms of timing 
and type.1 Additional markers are warranted to identify early stage patients at higher risk of recurrence, 
in order to offer patient-tailored follow up or adjuvant treatments. Currently, evidence has shown that 
the specific malignancy and biological features of a cancer depend not only on its genetic 
abnormalities, but also on the interplay between cancer cells and micro-environment. The relationship 
between the tumour and host’s immune system is particularly intriguing, especially considering that 
drugs targeting these pathways have shown a significant clinical efficacy in multiple tumour types.2 
Histological regression in melanoma is a paradigmatic example of this phenomenon. Some authors 
found no association between regression and melanoma prognosis,3 while other research groups 
reported a significant correlation between them.4–6 This discordance could be due to several factors 
including the heterogeneity of patient populations, as well as the different research methods applied, 
but what matters most is probably the lack of standardised histological criteria for its assessment. In 
particular, there is no agreement among pathologists in defining regression or in its sub-classification.7 
 
Tumour-infiltrating lymphocytes (TILs) have been identified as a favourable prognostic marker across 
multiple cancers including breast, ovarian, and colon cancer neoplasms and may serve as a surrogate 
indicator of the strength of the host anti-tumour immune response.8 TIL and histological regression are 
 two distinct, sometimes overlapping, phenomena of the melanoma biology that still deserve better 
explanation in order to differentiate them.  
 
The composition of the regression infiltrate has been partially characterised. Effector and suppressor T 
cells, B cells, natural killer cells, macrophages, and dendritic suppressor cells, can all impart competing 
immuno-stimulatory or immunosuppressive effects within the tumour microenvironment. 
 
The first aim of this study was thus to describe and histologically characterise the regression 
phenomenon in melanoma, assessing its impact on survival. The second aim was to evaluate the 
phenotype of the infiltrating lymphocytes comparing regressed and not regressed areas in order to 
identify cell subsets related to the phenomenon of histological regression. 
 
 
METHODS 
 
Study population 
 
A cohort of 70 consecutive patients with primary cutaneous melanoma attending the Dermatologic 
Clinic in Turin between January 2003 and December 2014 were enrolled in the study. All patients 
signed a consent form to give permission to include their biological sample in a biobank, and the study 
was approved by the local ethics committee. In order to perform an optimal evaluation of the histo-
morphological parameters, only melanoma samples with complete removal of the lesion and in which 
the entire thickness of the neoplasm was submitted to histological examination were included. 
Therefore, shave and punch biopsies, partial excisions and samples with too little/poor material were 
excluded from the study. In addition, a second cohort of 28 not regressed melanomas was used to 
compare the immunophenotypic composition of the TIL. Patient demographics, clinical, pathological, 
and follow-up information were prospectively recorded and updated on an internal database. For each 
case, the inflammatory regression areas were assessed (TIL inside regression area, TIL-IRA). In 
addition, one or more areas including inflammatory cells intimately associated with the tumour cells 
outside the regression area (TIL-ORA) were analysed for each case if present, and in the control series 
(TIL-CTRL).  
 
For full details regarding histopathological review, and immunophenotypical evaluation of TIL, 2,9–13 
see the Supplementary Methods (Appendix A). 
 
Morphological evaluation of histological regression13,14 
 
Histological regression: definition and phases 
 
Regression was defined and classified as follows: (i) early phase as a dermal tumour area with a dense 
mononuclear infiltrate composed mainly of lymphocytes, histiocytes and melanophages that actively 
infiltrate the neoplastic nests and at least partially replace neoplastic melanocytes; (ii) late phase as a 
dermal or epidermal area with disappearance of neoplastic cells and their replacement with dense 
 fibrous tissue, melanophages, dilated vessels and focal or missing residual lymphocytic infiltration in 
the dermis. 
 
Histological regression: ratio/percentage 
 
Once the presence of one or more regression areas was established, the regression/tumour area ratio 
was calculated as the ratio between the linear extension of regression areas and tumour. If regression 
was present on multiple tumour samples, the mean of the measurements made on all the slides was 
considered. In case of multiple regression foci on the same section, the sum of the different areas was 
considered. If regression was present in <5%, the lesion was considered as not regressed. Extensively 
regressed melanoma (>75%) was not considered eligible for the study. Regression >75% in horizontal 
extension according to the College of American Pathologists (CAP) definitions was not considered 
eligible for the study because in our experience it is present in only 4% of cases;15 for this reason, we 
focused our analysis on the prognostic role of tumour regression <75%. 
 
Histological regression: distribution/topography 
 
In addition, the predominant distribution pattern of regression was evaluated (peripheral if present on 
the sides of the tumour, basal if distributed along the stromal-tumour interface, and intra-tumoural if 
central and completely surrounded by the neoplastic cells).  In order to avoid an overlap with TIL, the 
key feature of regression was the evidence of destruction of neoplastic cells defined as ‘necrosis or 
apoptosis or whole disappearance of malignant tumour cells or apparent partial or total active 
destruction of melanocytic tears with replacement by inflammatory cells or fibrosis or melanophages’. 
Areas of ulceration or those intimately associated or adjacent to it were not considered. 
 
Statistical analysis 
 
The specific inflammatory infiltrates (TIL-IRA, TIL-ORA, TIL-CTRL) features and associations with 
clinicopathological characteristics were assessed using the chi-square test and the non-parametric test. 
Specifically, the p values in Table 1 were calculated as follows: if the variable had categorical data, the 
chi-squared test was performed; if the variable had continuous data, the Kruskal–Wallis rank sum test 
for median and the analysis of variance (ANOVA) for mean was performed. For more than two groups 
Tukey honestly significant difference (HSD) post-hoc test was performed. Logistic regression and post-
estimation receiver operating characteristic (ROC) curve were used to define optimal cut-off of 
regression related to relapse (>10%, >20%, >30%, >40%, >50%, >60% values were tested). Disease 
free interval (DFS) was calculated from the date of primary lesion diagnosis to the date of tumour 
progression/recurrence or last follow-up. Disease specific survival (DSS) was calculated from the date 
of primary lesion diagnosis to the date of death or last follow-up. Survival curves were estimated with 
the Kaplan–Meier method and compared using the log-rank test.  
 
 
RESULTS  
 
Clinicopathological characteristics of enrolled patients 
 
Clinicopathological characteristics are reported in Table 1. Of the 70 patients included with histological 
regressed melanoma, 39 (56%) were males and 31 (44%) females. Median age was 58 years (range 23–
78). Primary tumours were on the trunk in 58.6% of cases (41/70), followed by lower limbs (22/70, 
 31.4%), upper limbs (4/70, 5.7%) and head/neck (3/70, 4.3%). The most represented histotype was 
superficial spreading melanoma (56/70, 80%). Mean Breslow thickness was 2.73±2.10 mm.  The most 
represented Clark level was IV (71.4%, 50/70).  Ulceration was present in 33% of the lesions (23/70). 
Mitotic count ≥1/mm2 was present in 61% (43/70); 38.5% (27/70) showed diffuse neo-angiogenesis 
and 48.6% (34/70) had vascular invasion. In 20 cases (28.6%), TILs were described as ‘brisk’. There 
was metastatic involvement of the sentinel lymph node in 37% (26/70). 
 
According to the AJCC classification, there were eight stage I (26%), 26 stage II (37%), 26 stage III 
(37%) patients. After a median follow up of 4.9 years (range 0.7–8.9), 21/70 patients showed disease 
progression (30%), and subsequently 15 died of melanoma during follow up (21.4%). The pattern of 
first progression was: 12 regional metastases (12%) [four lymph node metastases in the same SLNB 
negative basin (false negative SLN biopsy), seven regional skin metastases, one lymph node metastasis 
into the parotid gland] and 13 (18%) distant metastasis. During follow-up, of 12 patients with first 
progression at regional site, four were free of disease after the surgical resection of the metastasis, three 
patients showed a de novo skin recurrence, one patient had lymph node metastasis and four patients 
progressed in a distant site (2 in the lung, 2 in the liver). 
 
Histological regression evaluation 
 
Percentage/ratio 
 
Median percentage of regression was 15% (range 5–75) (Table 1). After logistic regression and post-
estimation ROC analyses, a cut-off value of 10% was identified as statistically significant towards a 
more favourable course [odds ratio (OR) 0.35, confidence interval (CI) 0.12–0.98, p=0.048]. Patients 
with less than 10% of regression showed a higher Breslow thickness compared to the others 
(3.64 ± 2.32 mm vs 2.29 ± 1.85 mm, p=0.015), a higher prevalence of ulceration (56% vs 21%, 
p=0.003) and a higher prevalence of a mitotic count ≥1/mm2 (82% vs 51%, p=0.011). There were no 
differences concerning other variables adopting the 10% cut-off value (Table 1). We identified 46 
‘early’ and 24 ‘late’ regressed melanomas, respectively; no differences were observed on the basis of 
regression cut-off (17/23 early cases in ≤10% vs 29/47 early cases in 10–75%, p=0.312). 
 
DFS was significantly longer in patients with more than 10% of histological regression: in particular, at 
1 year of follow-up, 97.8% of the patients with >10% regression were disease free compared to the 
65.2% of patients with regression <10%, while at 5 years the rates were 73.1% and 48.7% (p=0.005), 
respectively (Fig. 1A). 
 
Concerning DSS, no significant difference was reached between regressed and not regressed tumours, 
even if the curve of the group with regression >10% looked more favourable in terms of prognosis. 
Percentages of survival at 1 year were 97.8% vs 82.6% and 84.6% vs 68.2% at 5 years, respectively 
(p=0.07) (Fig. 1B). 
 
TIL immunophenotype evaluation   
 
A total of 67 cases out of 70 histological regressed melanomas and 28 control melanomas were used 
for these analyses (Table 2), while three cases had insufficient material to perform all the 
determinations.  
 
The control cohort of not regressed melanomas used for comparing the immunophenotype had a mean 
 Breslow thickness of 2.61±1.29 mm, the median age at diagnosis was 53, 12/28 had ulceration of 
primary melanoma. There were no significant differences in the classical prognostic melanoma features 
between regressed and not regressed melanomas. 
 
The distribution of immunophenotype in TILs in both regressed and not regressed lesions is reported in 
Table 2. No differences were observed in the immunophenotype between TIL-IRA and TIL-ORA in 
the 49 analysable cases when evaluating the CD3, CD4, CD8 sub-populations. Conversely, differences 
were detected in FOPX3/CD4 ratio in different subgroups (10.1±9.28 TIL-IRA vs 23.3±21.8 TIL-ORA 
vs 38.4 ± 25.4 TIL-CTRL; p<0.001) (Fig. 2). 
 
FOXP3/CD4 evaluation and correlation with regression 
 
FOXP3/CD4 ratio was lower in TIL-IRA compared to TIL-ORA (10.1±9.28 vs 23.3±21.8, p=0.0004), 
but both of them were significantly lower compared to TIL-CTRL (38.4±25.4, p=0.0016) (Table 2). In 
particular, we evaluated the differences according to the extent of the regression (≤10% vs 10–75%). 
FOXP3/CD4 ratio in TIL-CTRL (38.4±25.4) was higher than the ratio observed in TIL-ORA of 10–
75% (21.8±17.9, p=0.0361) (Supplementary Table 1, Appendix A). When looking at differences of 
immunophenotype rate between TIL-CTRL and TIL-IRA, we observed a higher ratio of FOXP3/CD4 
in the TIL-CTRL subset compared to both ≤10% and 10–75% categories (38.4±25.4 vs 9.7±9.87 vs 
10.3±9.10, p<0.001) (Supplementary Table 2, Appendix A).  Supplementary Table 3 (Appendix A) 
reports data on regressed lesions: TIL-ORA (≤10% and 10–75% subgroups) showed a higher ratio of 
FOXP3/CD4 (26.0±28.2 and 21.8±17.9) compared to TIL-IRA (≤10% and 10–75% subgroups) 
(9.7±9.87 and 10.3±9.10).  
 
PD1/CD4 evaluation  
 
PD1/CD4 ratio in TIL-IRA and TIL-ORA were significantly lower compared to TIL-CTRL (4.9±5.5 
and 6.9±7.6 vs 12.7±6.9, p<0.001) (Table 2), while no difference was detected in PD1/CD4 ratio 
between TIL-IRA and TIL-ORA in regressed lesions [4.9±5.5 vs 6.9±7.6, p=not significant (ns)].  
 
Similarly, PD1/CD4 ratio between TIL-IRA≤10% VS TIL-IRA 10–75% was not statistically different 
(5.7±5.3 vs 4.5±5.6, p=ns; Supplementary Table 2, Appendix A). Moreover, PD1/CD4 ratio in TIL-
ORA was higher in lesions with ≤10% of regression compared to TIL-ORA in lesions with 10–75% 
regression (10.5±8.9 vs 3.1±2.9, p=0.0004) (Supplementary Table 1, Appendix A). 
 
When looking at differences in immunophenotype rates between TIL-CTRL and TIL-IRA in ≤10% or 
10–75% categories, we observed a higher ratio of PD1/CD4 in TIL-CTRL compared to both (12.7±6.9 
vs 5.7±5.3, p<0.007; and 12.7±6.9 vs 4.5±5.6, p<0.001) (Supplementary Table 2, Appendix A). For 
TIL-CTRL and TIL-ORA in ≤10% or 10–75% categories, we observed a higher ratio of PD1/CD4 in 
TIL-CTRL compared to 10–75% regressed melanoma (12.7±6.9 vs 10.5±8.9, p=ns; and 12.7±6.9 vs 
3.1±2.9, p<0.0004) (Supplementary Table 1, Appendix A). In regressed lesions, (Supplementary Table 
3, Appendix A) TIL-ORA in lesions with ≤10% showed a higher PD1/CD4 ratio compared to TIL-IRA 
in both categories.  
 
 
DISCUSSION 
 
Melanoma is considered an ‘immunogenic’ cancer because it is often associated with lymphocytic 
 infiltration and is capable of spontaneous regression.14–17 Those phenomena are strictly related, share 
some similarities, but probably represent different time-points and different mechanisms during the 
biological history of this tumour. Although the lymphocytic infiltrate has been described as a 
favourable prognostic feature,18 complete agreement on the role of histological regression has not been 
reached to date; indeed, either a negative or protective role on prognosis has been attributed to 
regression.4–6,19 Moreover, it has been suggested that early immune activation could explain the 
different immunotherapy response rates in clinical practice.20 
  
After revision of slides and evaluation of the extent of regression, we identified a quantitative cut-off 
value (10%) of histological regression associated with a different outcome. In fact, this cut-off 
maintained its prognostic role in terms of DFS by survival analysis, marking the difference between the 
not regressed (≤10%) and the ‘true’ regressed melanomas (10–75%). A similar regression extent cut-
off in dermoscopy has been associated with a different tumour molecular landscape in terms of copy 
number variation, which represents a marker of tumour aggressiveness.21 For DSS, no significant 
difference was reached between regressed and not regressed tumours; this finding can be related to 
overlaps with the widespread availability of immunomodulatory therapy in recent years, which might 
differentially affect survival in melanoma patients.22  
 
In order to explain the different behaviour of regressed lesions, we analysed the immunophenotype of 
the recruited lymphocytes within and outside the ‘regression’ areas in regressed lesions compared to a 
control group without regression.  
 
In our study, a lower rate of FOXP3/CD4 positive cells was observed in TIL-IRA and TIL-ORA in 
regressed melanoma compared to not regressed melanoma (TIL-CTRL). The FOXP3+ T-reg 
population has been described to decrease the innate and acquired response against the tumour through 
a mechanism which is physiologically involved in protecting against autoimmunity23,24 and has also 
been associated with different progression and survival rates in melanoma patients.18,24–26 Conversely, 
the absolute number of FOXP3+ cells was not significantly different between the groups in our series. 
When considering the FOXP3/CD4 ratio, it was inversely associated with histological regression, thus  
reflecting a different immunotolerance status between regressed and not regressed melanoma, 
potentially representing an early immunophenotypic marker of inactivation of the immune system. This 
finding is also supported by evidence that in metastatic melanoma FOXP3+ tumour-infiltrating 
immune cells are a potential predicting biomarker of response to treatment and survival. Balatoni et al. 
showed that the strongest predictor of ipilimumab treatment response was the density of FOXP3+ cells 
infiltrating lymph node metastases; moreover Di Gennaro et al. reported that electrochemotherapy 
induces a local response in skin melanoma metastasis by a lymphoid infiltrate characterised by a 
decrease in CD4+FOXP3+Treg cells.27–29 
 
Similarly, we demonstrated a different count of PD1+ out of the total CD4+ count in the control group 
(without regression) compared to the regressed group. The PD1/PDL1 axis maintains a balance 
between tolerance and autoimmunity, thus cancer cells under selective pressure can exploit this 
signalling pathway with lymphocytes to decrease the immune response. PD1/PDL1 interaction inhibits 
T lymphocyte proliferation, survival, and effector functions, induces apoptosis of antigen-specific T 
cells, and promotes the differentiation of CD4+ T cells into FOXP3+ regulatory T cells. Moreover new 
evidence is suggesting that the peritumoural and the perimetastases infiltrate can be a potential 
therapeutic target in melanoma.26,30–33 From this point of view, the histological regression depends on 
the immune microenvironment and can be considered an indicator of a more efficient immune system 
exploitable for daily clinical practice.34 
  
Limitations of the present study are due to the relatively low prevalence of regression in melanoma 
which, together with the need for adequate representative tissue, results in a relatively small sample 
size.  Moreover, we have considered only lesions with extensive regression up to 75%, because 
melanomas with regression higher than 75% are extremely rare and harbour uncertain clinical 
behaviour.15,35 The limited number of samples could help explain why statistical significance was not 
achieved in survival analysis, even though a trend was observed; this finding is probably also due to the 
increased use of immunomodulatory therapies in recent years. Another potential limitation could be the 
intrinsic operator-dependency in immunophenotype assessment, but we tried to overcome it by 
employing multiple independent observers.  
 
Despite these potential drawbacks, based on these results we can suggest that histological regressed 
melanomas represent a heterogeneous group in terms of prognosis, possibly due to different 
immunomodulatory mechanisms which the can affect the activity of TILs. Caution should be advised 
when interpreting the prognostic meaning of these characteristics, but an important observation is that a 
regression of 10–75% should be considered a biologically and clinically significant phenomenon 
impacting survival. The observed heterogeneity in terms of immunophenotype between the different 
samples and tumour areas highlights the importance of target assessment and selection when devising 
future treatment strategies, and live adoptive cell therapy.36 Following our results, further studies are 
encouraged analysing the immunophenotype of histological regression, especially evaluating its 
correlation with response to therapies. 
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 FIGURE LEGENDS 
  
Fig. 1 (A) Disease free survival and (B) disease specific survival of melanoma patients stratified for the 
extension of histological regression.  
 
Fig. 2 (A) Low power H&E of a regression area (IRA): a rich inflammatory infiltrate is present with 
lymphocytes and melanophages replacing neoplastic cells (arrows). (B) Low power H&E of an area 
outside regression (ORA): an inflammatory infiltrate is present, although replacement of neoplastic 
cells is not (arrows). (C) Low power FOXP3 immunohistochemical staining showing few positive cells 
within the regression area (arrows). (D) Low power FOXP3 immunohistochemical staining showing 
multiple positive cells within the tumour infiltrating lymphocytes (arrows). 
 
 
 
 
 
 
  
 Table 1 Clinical characteristics in regressed and not regressed melanomas 
 
 Histological regression 
stratified 
Histological 
regression 
(5–75%) 
 (n=70) 
No histological 
regression 
(CTRL) 
 (n=28) 
p* 
5–10% 10–75% p 
Age, median (interval) 55 (34–78) 59 (23–78) 0.551 58 (23–78) 53 (27–83) 0.432 
Gender   0.149   0.250 
Female 13 18  31 16  
Male 10 29 39 12 
Primary site   0.078   0.141 
Head/neck 2 1  3 1  
Trunk 9 32 41 13 
Upper extremities 1 3 4 6 
Lower extremities 11 11 22 8 
Histotype   0.245   0.291 
SSM 16 40  56 23  
ALM 5 6 11 2 
Other 2 1 3 3 
Breslow thickness, 
mm±SD 
3.64±2.32 2.29±1.85 0.015 2.73±2.10 2.61±1.29 0.769 
Breslow AJCC   0.036   0.209 
≤1 3 13  16 3  
1–2 5 14 19 8 
2–4 5 14 19 13 
>4 10 6 16 4 
Clark   0.688   0.586 
3 7 11  18 10  
4 15 35 50 17 
5 1 1 2 1 
Ulceration   0.003   0.351 
No 10 37  47 16  
Yes 13 10 23 12 
Mitosis   0.011   0.105 
<1 4 23  27 6  
≥1 19 24 43 22 
Neoangiogenesis   0.328   0.475 
Absent/mild 16 27  43 15  
Present 7 20 27 13 
Inflammatory infiltrate   0.013   0.795 
Scarce 14 14  28 12  
Present 9 33 42 16 
Vascular invasion   0.635   0.149 
Absent 16 30  46 14  
Present 7 17 24 14 
SLN status   0.416   0.056 
Negative 16 28  44 12  
Positive 7 19 26 16 
No. metastatic LN   0.615   0.185 
0 16 28  44 12  
1–2 6 16 22 15 
3–4 0 2 2 1 
>4 1 1 2 0 
AJCC stage   0.181   0.182 
I 4 14  18 3  
II 12 14 26 10 
III 7 19 26 15 
 Brisk infiltrate   0.147   0.215 
No 19 31  50 17  
Yes 4 16 20 12 
 
AJCC, American Joint Committee on Cancer; ALM: acral lentiginous melanoma; LN, lymph node; SD, standard deviation; 
SLN, sentinel lymph node; SSM, superficial spreading melanoma. 
*Those tests are referring to the total of regressed melanoma towards the not regressed ones. 
 Table 2 TIL immunophenotype in regressed and not regressed lesions 
 
Population TIL-CTRL 
(A) (n=28) 
TIL-ORA  
(B) (n=49) 
TIL-IRA 
(C) (n=67) 
Tukey HSD post-hoc test 
CD3, n° cell/mm2 523.8±386.4 585.14±426.2 500.2±337.3 0.4874  
CD20, n° cell/mm2 95.5±132.76 76.12±116.48 64.8±98.9 0.4757  
CD4, n° cell/mm2 238.3±159.9 305.6±233.6 278.0±182.5 0.3570  
CD8, n° cell/mm2 297.5±235.2 299.9±224.6 249.3±184.1 0.8332  
CD4/CD8 0.93±0.38 1.11±0.61 1.27±0.53 0.0170 A vs C 0.0148 
CD25, n° cell/mm2 38.9±37.6 35.7±46.7 27.1±27.2 0.2696  
CD123, n° cell/mm2 7.3±11.6 5.4±10.7 3.0±5.4 0.0783  
FOXP3, n° cell/mm2 91.2±72.5 62.8±73.9 52.7±66.3 0.0541 A vs C 0.0420 
CD4/CD3, % 49.8±17.2 54.2±19.8 58.8±18.3 0.0872  
FOXP3/CD4, % 38.4±25.4 23.3±21.8 10.1±9.28 <0.001 A vs B 0.0016,  
A vs C <0.001,  
B vs C 0.0004 
PD1, n° cell/mm2 28.4±42.5 15.1±23.1 12.9±21.1 0.0380 A vs C 0.0325 
PD1/CD4, % 12.7±6.9 6.9±7.6 4.9±5.5 <0.001 A vs B 0.0016,  
A vs C <0.001 
Melanophages, n° 
cell/mm2 
77.2±81.8 191.8±179.8 0.0017  
 
HSD, honestly significant difference. 
